drugset
drugset / Trial / NCT05226338

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

NCT05226338 ↗

Phase 1 Completed 18 enrolled InventisBio Co., Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects

Timeline

Start
2021-10-27
Primary completion
2021-12-23
Completion
2022-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject TARAGARESTRANT Small molecule — —

Indications

No indication recorded.